Solid forms of a compound
AssigneeDenali Therapeutics Inc.
InventorsChristopher R.H. Hale, Yingqing Ran, Anantha Sudhakar
Life of this patent
Estimating the term…
Abstract
Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamide, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
Claims23
Form C polymorph of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pent-1-yl]acetamide, that exhibits an X-ray powder diffraction pattern having peaks expressed in ±0.2 degrees 2-theta at 18.5, 23.3, 25.1, and 25.8, wherein the X-ray powder diffraction pattern is made using CuKα radiation.
Form A polymorph of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pent-1-yl]acetamide that exhibits an X-ray powder diffraction pattern having peaks expressed in ±0.2 degrees 2-theta at 22.2, 22.6, and 22.9, wherein the X-ray powder diffraction pattern is made using CuKα radiation wherein the compound is micronized.
Dependencies are inferred from the claim text.